{
  "investment_performance": [
    "No fund-level IRR, MOIC, or DPI metrics were disclosed in this update.",
    "Key programs progressing through preclinical and early clinical stages include Free001 (ketamine IV solution) and Free008 (psychedelic therapeutic for cardiovascular and psychiatric use).",
    "Series B fundraising is underway with a target raise of $30\u201350M. Lead investor due diligence is in late stages, with $30M to be unlocked upon planned Phase 2 topline data for Free001 and Phase 1a/b data for Free008.",
    "Additional capital (up to $50M) may support CMC development and Phase 3 (Free001) and Phase 2 (Free008) trial acceleration."
  ],
  "key_takeaways": [
    "The company has soft commitments for ~15\u201320% of the Series B round already from insiders and seeks broader early interest to support term sheet negotiations by December 17.",
    "Free001 Phase 2: Prototyping is near completion for two IV bag options. Development batch testing is planned for early Q1 2026, with Phase 2 study targeted for Q2 2026, contingent on Series B close.",
    "Free008 Phase 1: Experienced delays due to Chinese regulatory shifts. A new US-based CRO has been secured. Cardiovascular tox work begins next month, with UK Phase 1 trial planned for early 2027.",
    "Preparing for a Type D meeting with the FDA in early Q1 2026 to determine if Phase 1 trials for Free008 can proceed in the US to gain time efficiency."
  ],
  "business_updates": [
    "Strong external validation is seen in industry M&A and positive trial data, including:",
    "AbbVie\u2019s $1B+ investment in Gilgamesh\u2019s psychedelic drug.",
    "Atai/Beckley merger and Supernus\u2019 $561M Sage acquisition.",
    "Compass Pathways\u2019 and Atai\u2019s positive Phase 2b readouts.",
    "Freedom Bio was active across several high-profile industry events and conferences:",
    "8th Neuropsychiatric Drug Development Conference (Boston).",
    "One Mind Festival (Napa) \u2013 selected participant.",
    "Wilson Sonsini Biopharma Summit and Wells Fargo Private Track.",
    "Panel participation at Harvard Business School Healthcare Conference with Gilgamesh and others.",
    "Upcoming presentations at Evercore, Citi, Lucid, and JPM Healthcare Conferences signal continued engagement with top-tier investors and strategic partners."
  ]
}